[Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Miki
Tsuneharu
T
Department of Urology, Kyoto Prefectural University of Medicine.
Okihara
Koji
K
D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy; D043823:Taxoids / Q000627:therapeutic use; D000077211:Zoledronic Acid
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; D000077143:Docetaxel; D000077211:Zoledronic Acid